Biomarin Pharmaceutical Inc
F:BM8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Biomarin Pharmaceutical Inc
F:BM8
|
US |
|
Banco Santander SA
F:BSD2
|
ES |
|
Mediobanca Banca di Credito Finanziario SpA
MIL:MB
|
IT |
|
H
|
Healthequity Inc
F:2HE
|
US |
|
Verbund AG
F:OEW
|
AT |
Wall St Price Targets
BM8 Price Targets Summary
Biomarin Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for BM8 is 78.99 EUR with a low forecast of 47.86 EUR and a high forecast of 108.55 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BM8's stock price target?
Price Target
78.99
EUR
According to Wall Street analysts, the average 1-year price target for BM8 is 78.99 EUR with a low forecast of 47.86 EUR and a high forecast of 108.55 EUR.
What is the Revenue forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
9%
Over the last 14 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 8 years is 9%.
What is the Operating Income forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
14%
The compound annual growth rate for Operating Income over the next 8 years is 14%.
What is the Net Income forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
27%
The compound annual growth rate for Net Income over the next 8 years is 27%.
